Dogwood Therapeutics Inc (DWTX)

Currency in USD
4.892
+0.136(+2.86%)
Closed·
After Hours
4.760-0.132(-2.70%)
·
DWTX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
DWTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.7545.080
52 wk Range
1.62029.280
Key Statistics
Prev. Close
4.756
Open
4.765
Day's Range
4.754-5.08
52 wk Range
1.62-29.28
Volume
31.13K
Average Volume (3m)
52.71K
1-Year Change
4.47%
Book Value / Share
-9.37
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DWTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
17.000
Upside
+247.51%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Dogwood Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy

Dogwood Therapeutics Inc Company Profile

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and IMC-2, a combination of valacyclovir and celecoxib in Phase 2 clinical trial for the treatment of long-COVID and post-acute sequelae of COVID-19 infection. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2012 and is based in Alpharetta, Georgia.

Compare DWTX to Peers and Sector

Metrics to compare
DWTX
Peers
Sector
Relationship
P/E Ratio
−0.4x−1.5x−0.5x
PEG Ratio
0.00−0.070.00
Price/Book
−0.5x0.8x2.6x
Price / LTM Sales
-41.3x3.3x
Upside (Analyst Target)
128.7%472.0%43.4%
Fair Value Upside
Unlock43.9%7.1%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 17.000
(+247.51% Upside)

Earnings

Latest Release
May 09, 2025
EPS / Forecast
-8.45 / -0.05
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

DWTX Income Statement

People Also Watch

2.0400
DARE
-9.73%
3.2900
SNGX
+2.81%
170.89
ALAB
-2.01%
0.383
CLSD
-7.03%
4.7100
CLRB
-1.46%

FAQ

What Stock Exchange Does Dogwood Therapeutics Trade On?

Dogwood Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Dogwood Therapeutics?

The stock symbol for Dogwood Therapeutics is "DWTX."

What Is the Dogwood Therapeutics Market Cap?

As of today, Dogwood Therapeutics market cap is 9.35M.

What Is Dogwood Therapeutics's Earnings Per Share (TTM)?

The Dogwood Therapeutics EPS (TTM) is -19.87.

From a Technical Analysis Perspective, Is DWTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Dogwood Therapeutics Stock Split?

Dogwood Therapeutics has split 1 times.

How Many Employees Does Dogwood Therapeutics Have?

Dogwood Therapeutics has 12 employees.

What is the current trading status of Dogwood Therapeutics (DWTX)?

As of 08 Aug 2025, Dogwood Therapeutics (DWTX) is trading at a price of 4.89, with a previous close of 4.76. The stock has fluctuated within a day range of 4.75 to 5.08, while its 52-week range spans from 1.62 to 29.28.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.